Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
NVO heads into Q2 earnings under pressure as slowing injectable GLP-1 momentum, pricing headwinds and fierce competition cloud the near-term outlook.
Novo Nordisk Stock Sinks on Disappointing Heart Drug Trial Results
U.S.-listed shares of Novo Nordisk closed Thursday up just 1% this year. They look likely to drop into the red today.
Novo Nordisk Shares Drop After Drug Candidate Fails in Cardiovascular Trial
Stock was down 9.5% after the company's experimental medicine ziltivekimab didn't achieve the expected risk reduction for major cardiovascular events.
Novo Nordisk shares dive 9% after heart medicine fails trial
Novo Nordisk shares dive 9% after heart medicine fails trial
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?
Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.
Why shareholders are suing Novo Nordisk over next-generation weight-loss drug
Novo Nordisk shareholders allege the company misled investors about a key clinical trial for its next-generation weight-loss drug CagriSema. A U.S. judge on Tuesday allowed parts of that lawsuit to move forward.
Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing
Novo Nordisk (NVO) reached $50.96 at the closing of the latest trading day, reflecting a +2.6% change compared to its last close.
Novo Nordisk: Sensitivity Analysis Of Oral Wegovy's Gross Profits Supports Modest Buy
Novo Nordisk (NVO) is rated a Modest Buy with a raised price target of $80, driven by oral Wegovy's rapid market adoption. Oral Wegovy has achieved over 3 million prescriptions in five months, with 80% from GLP-1–naïve patients, expanding the addressable market. Sensitivity analysis suggests a base case wherein oral Wegovy could generate $12–$15 billion in annual gross profit under realistic assumptions.
Novo Nordisk Remains A Generational Buying Opportunity Ahead Of Q2 Earnings
Novo Nordisk (NVO) has experienced a 30%+ stock decline since mid-2024, extending its ongoing downtrend. Novo Nordisk reports Q2 results next week, with investors focused less on near-term beats and more on management's confidence in transformation plans. Oral Wegovy has rapidly gained prescriptions, attracting predominantly new GLP-1 patients and expanding Novo's addressable market without materially cannibalizing established treatments.
Novo Nordisk: Initiating Buy, Calling The Bottom
I initiate Novo Nordisk with a BUY rating and $68 price target, viewing current valuation as an attractive entry point. Oral Wegovy is expanding the treated obesity market, not just cannibalizing injectables, supported by strong prescription growth and efficacy data. Pipeline assets like high-dose Wegovy, CagriSema, and Zenagamtide offer risk-adjusted lifecycle support but face efficacy and tolerability challenges.
Novo Nordisk: Mr. Market Is Pricing In Success, But It's Too Early To Bank On That
Novo Nordisk: Mr. Market Is Pricing In Success, But It's Too Early To Bank On That
Here's Why Novo Nordisk (NVO) Fell More Than Broader Market
Novo Nordisk (NVO) closed the most recent trading day at $48.19, moving 2.41% from the previous trading session.
